markets.businessinsider.com
Cure8 news brief
Why This Matters
Early Phase 2 data suggest VTX958 may improve endoscopic healing and lower inflammatory markers in Crohn’s disease, outcomes that matter for long-term disease control. The report also notes the trial missed its primary symptom endpoint, so results are preliminary.
Who Should Pay Attention
Patients with Crohn’s disease, clinicians treating IBD, researchers and drug developers, and people monitoring emerging oral therapies (TYK2 inhibitors).
Study Snapshot
Story typeBusiness news
Evidence typePhase 2 clinical trial
Source depthFull source text
What To Know
VTX958 is an experimental TYK2 inhibitor being studied in Crohn’s disease. In Phase 2, the company highlights strong, dose-dependent endoscopic improvements and associated drops in CRP and fecal calprotectin, despite the study missing its primary CDAI endpoint.
The company plans to present fuller Phase 2 and 52-week LTE results at the ECCO meeting; those fuller results will be more useful for judging safety and durability of benefit. No new treatment recommendations follow from this press-style report.
Keep In Mind
Trial findings can depend on who was enrolled, what outcomes were measured, and how long people were followed. The original source has the study details.
Source Details
Review the original publication for the complete reporting, methods, and context.
Publicationmarkets.businessinsider.com
Indexed viaBing News
Source typeBusiness news
PublishedFeb 18, 2025, 5:30 AM
Content availableFull source text
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Ventyx Biosciences Announces Presentation of Data from the Phase 2 Trial of Allosteric TYK2 Inhibitor VTX958 in Crohn’s Disease at ECCO 2025
This reports Phase 2 clinical data for an oral TYK2 inhibitor (VTX958) in Crohn’s disease — a potential new oral treatment approach. The drug showed meaningful endoscopic improvements and reductions in inflammatory...
Phase 2 Trial: Ventyx's VTX958 Shows Strong Endoscopic Response in Crohn's Disease ...
New oral TYK2 inhibitor data show promise on endoscopic healing and inflammatory markers in Crohn’s disease, which is important because oral treatment options are limited. However, the trial missed its main symptom-based...
A Longitudinal Disease Progression Model Characterizing Endoscopic Response and Remission in Crohn's Disease.
Understanding and quantifying placebo-driven endoscopic changes can improve design and interpretation of Crohn’s disease trials, which may ultimately speed development of effective therapies and clarify who benefits from...